Our expert team has written hundreds of insightful articles on all aspects of regulatory affairs, pharmacovigilance, clinical trials, compliance and more. Here, we are highlighting some of the best writing from our recent archive in #ICYMI. In this latest edition of In Case You Missed It from Acorn Regulatory we are featuring articles on issues as diverse as smart packaging, the common missteps on CEP’s and much more. more than 400 orphan designated drugs at clinical trial phase. As the sector continues to grow there has been a tendency for facts about orphan drugs to get lost in the midst of issues concerning specific patients needs, pricing and availability. In this article we look at some facts about orphan designation that companies considering entering the sector should be aware of. Read more here.